01; b) T lim with selleck compound NaHCO3 (solid line) and placebo (dashed line) on the 5 days of testing are presented as group mean ± SD (n = 8). The NaHCO3 intervention resulted in a significantly higher [HCO3 -]

relative to placebo (F (1,7) = 118.71, P < 0.001, ηp 2 = 0.94; MK-4827 manufacturer Table 1). [Na+] increased after NaHCO3 (F (1,7) = 12.44, P = 0.012, ηp 2 = 0.68) but remained constant with placebo supplementation. [Na+] did not significantly change over time (F (1,7) = 0.49, P = 0.509, ηp 2 = 0.08) with either condition. The mean ABE were significantly higher during the NaHCO3 Selleck LDN-193189 compared to the placebo trials (F (1,7) = 100.42, P < 0.001, ηp 2 = 0.94), but not between days of testing (F (1,7) = 0.01, P = 0.920, ηp 2 = 0.00). Blood pH was increased with NaHCO3 supplementation (F (1,7) = 42.04, P < 0.001, ηp 2 = 0.86), showing no change between the testing days (F (1,7) = 1.11, P = 0.327, ηp 2 =

0.14). There was a main effect for a PV increase during interventions (F (1,7) = 19.22, P = 0.003, ηp 2 = 0.73; Table 1) and days of testing (F (1,7) = 18.12, P = 0.004, ηp 2 = 0.72), as well as a significant intervention x time interaction (F (1,7) = 22.05, P = 0.002, ηp 2 = 0.76). Table 1 [HCO 3 - ], [Na + ], ABE, pH and PV 75 min after supplement ingestion on the first and the fifth day of testing with either NaHCO 3 or placebo supplementation   NaHCO3 Placebo   Day 1 Day 5 Day 1 Day 5 [HCO3 -] (mmol &z.ccirf;l-1) 32.4 ± 1.8*** 32.6 ± 2.7*** 26.4 ± 1.8 26.0 ± 1.1

[Na+] (mmol &z.ccirf;l-1) 142.1 ± 3.9* 142.4 ± 3.0* 138.1 ± 1.2 139.3 ± 5.5 ABE (mmol &z.ccirf;l-1) 8.4 ± 1.7*** 8.3 ± 2.3*** 2.7 ± 1.7 2.0 ± 0.9 pH 7.49 ± 0.02*** 7.48 ± 0.02*** 7.44 ± 0.02 7.43 ± 0.02 PV (%) 55.5 ± 2.3 62.6 ± 3.8†† 56.0 ± 1.7 55.9 ± 3.3 Values are mean ± SD (n = 8). [HCO3 -], blood bicarbonate concentration; [Na+], blood sodium concentration; ABE, actual base excess; PV, plasma volume. *P < 0.05, *** P < 0.001 relative to placebo at the same time point; †† P < 0.01 relative to day 1. The NaHCO3 ingestion resulted in a significant intervention x time interaction for total lean body Apoptosis inhibitor mass (F (1,7) = 7.77, P = 0.027, ηp 2 = 0.53; Table 2). In addition, total lean body mass raised over the five consecutive testing days in both conditions (F (2,14) = 10.97, P = 0.001, ηp 2 = 0.61; Table 2). Lean soft tissue mass of the legs did not change neither during the interventions (F (1,7) = 3.16, P = 0.119, ηp 2 = 0.31) nor across the days of testing (F (2,14) = 1.38, P = 0.283, ηp 2 = 0.17; Table 2). Table 2 Total lean body mass and lean soft tissue mass of the legs on the different days of testing with either NaHCO 3 or placebo ingestion   NaHCO3 Placebo   Day 1 Day 3 Day 5 Day 1 Day 3 Day 5 Total lean soft tissue (kg) 60.7 ± 4.8 61.7 ± 5.3*†† 62.0 ± 5.3*†† 60.5 ± 5.3 61.3 ± 5.4†† 60.6 ± 5.